🇺🇸 FDA
Pipeline program

BCMA CAR-T

IIT2025048

Phase 2 mab active

Quick answer

BCMA CAR-T for Multiple Myeloma, Plasma Cell Leukemia is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Multiple Myeloma, Plasma Cell Leukemia
Phase
Phase 2
Modality
mab
Status
active

Clinical trials